微信直播

AME译者招募|《结直肠癌》英文版面世,诚邀您成为中文版译者!

Published at: 2015年第1卷第S1期

关键词:

很高兴告知大家《结直肠癌》英文版即将与读者见面。作为 AME 旗下又一新力作,本书由上海交通大学医学院附属瑞金医院的郑民华教授、Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine 的 Daniel Haller教授担任主编。

结直肠癌发病率位居全球恶性肿瘤前列。历经 20 世纪后半叶近 50 年的发展,结直肠癌治疗已进入全新时代。随着多学科综合治疗策略的逐步推广,及以分子靶向治疗为代表的新型治疗手段的合理应用,晚期结直肠肿瘤的中位总生存期已逾 2 年。在源于各类循证医学证据的临床诊疗规范,以及基于分子标志物(组)及肿瘤生物学行为的个体化治疗领域,进展迅猛。《结直肠癌》一书围绕结直肠癌的流行病学和筛查、病理与分子生物学、临床表现、诊断与治疗、术后复发与转移的治疗、患者护理和心理问题等方面作了较为深入的剖析,旨在为相关领域的临床工作者和研究者提供一个结直肠癌诊疗、患者护理方面有价值的参考。

由郑民华教授和 Daniel Haller 教授领衔,《结直肠癌》汇集了十多个国家百余位作者及多个世界顶级癌症研究中心,如 The University of Texas M.D. Anderson Cancer Center, Johns Hopkins University School of Medicine, Roswell Park Cancer Institute, Memorial Sloan Kettering Cancer Center, Mayo Clinic, University of Oxford, Cambridge University Hospitals NHS Trust, Washington University in St. Louis 的经验和智慧。

在此,我们诚挚邀请您参与本书的翻译,希望本书的中文版能够帮助更多的中国结直肠癌医生、相关领域研究者以及将来有志从事相关研究事业的学生,最终惠及结直肠癌患者。本书的所有译文将由《结直肠癌》中文版编委会进行审校。

《结直肠癌》中文版编委会成员:

 

专家

单位

主编

郑民华

上海瑞金医院

副主编

叶颖江

北京大学人民医院

副主编

池畔

福建医科大学附属协和医院

副主编

李国新

南方医科大学南方医院

编委

杜晓辉

301医院

编委

李乐平

山东省立医院

编委

魏东

解放军150医院

编委

张海增

中国医学院科学院肿瘤医院

编委

崔滨滨

哈医大三院

编委

冯勇

中国医科大学盛京医院

编委

朱安龙

哈医大一院

编委

王锡山

中科院肿瘤医院

编委

丁克峰

浙江大学附属第二医院

编委

黄学峰

浙江大学附属邵逸夫医院

编委

应敏刚

福建省肿瘤医院

编委

程勇

重庆医科大学附属第一医院

编委

潘凯

深圳市人民医院

编委

潘志忠

中山大学附属肿瘤医院

编委

王自强

华西医院

编委

陶凯雄

武汉协和医院

编委

龚建平

武汉同济医院

编委

梁小波

山西省肿瘤医院

编委

赵青川

第四军医大学西京医院

编委

管文贤

南京鼓楼医院

编委

陆爱国

上海瑞金医院

编委

孙跃明

江苏省人民医院

编委

张卫

长海医院

编委

傅传刚

第二军医大学附属长海医院

 

领目录

1

Epidemiology and burden of colorectal cancer in Asia-Pacific region: what shall we do now?

2

Improved colorectal cancer screening: a new option and opportunity

3

Colorectal cancer screening: are stool and blood based tests good enough?

4

Is the ability of stool DNA test enough for practical use in colorectal cancer screening?

5

Leptin as a risk factor for the development of colorectal cancer

6

Risk of colorectal cancer after detection and removal of adenomas at colonoscopy

7

The bacteria-hypothesis of colorectal cancer: pathogenetic and therapeutic implications

8

The evolution of colorectal cancer genetics—Part 1: from discovery to practice

9

The evolution of colorectal cancer genetics—Part 2: clinical implications and applications

10

Extended RAS testing in metastatic colorectal cancer—Refining the predictive molecular biomarkers

11

TNF-α in obesity-associated colon cancer

12

Evolution of imaging in rectal cancer: multimodality imaging with MDCT, MRI, and PET

13

Local excision for early rectal cancer: transanal endoscopic microsurgery and beyond

14

A critical review of the role of local excision in the treatment of early (T1 and T2) rectal tumors

15

Complete mesocolic excision with central vascular ligation: is this the approach to improve colon cancer surgery oncological outcomes?

16

Complete mesocolic excision (CME) with central vessel ligation (CVL): a new standard in colon cancer surgery

17

Is lymph node metastasis the only concern in high-risk submucosal colorectal cancer following endoscopic resection?

18

The emerging role of neoadjuvant chemotherapy for rectal cancer

19

Hyperthermic intraperitoneal chemotherapic perfusion in colorectal cancer

20

Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer?

21

Novel radiation techniques for rectal cancer

22

Evidence behind use of orthovolt intraoperative radiotherapy and other techniques of IORT in recurrent colorectal cancer treatment

23

Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?

24

Oral tyrosine kinase inhibitors targeting VEGF-receptors in patients with metastatic colorectal cancer

25

Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib

26

Impact of the immune system and immunotherapy in colorectal cancer

27

Review of systemic therapies for locally advanced and metastatic rectal cancer

28

Therapeutic approaches in the management of locally advanced rectal cancer

29

Multidisciplinary approach and targeted agents increase resectability of liver-limited metastases from colorectal cancer

30

Predicting complete response: is there a role for non-operative management of rectal cancer?

31

Management of oligometastatic rectal cancer: is liver first?

32

Liver-directed therapies in metastatic colorectal cancer

33

Non-operative therapies for colorectal liver metastases

34

Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases

35

The surgical treatment of patients with colorectal cancer and liver metastases in the setting of the “liver first” approach

36

Intraoperative margin re-resection for colorectal cancer liver metastases

37

Potential use of Doppler perfusion index in detection of occult liver metastases from colorectal cancer

38

Addressing sexual dysfunction in colorectal cancer survivorship care

39

Diet and supplements and their impact on colorectal cancer

40

Psychosocial issues in colorectal cancer survivorship: the top ten questions patients may not be asking

 

认领方法

Step 1:关注「AME科研时间」(amegroups)公众号。

 

Step 2:

  1. 请登录 AME 认领系统认领:http://rl.amegroups.com/User/Assignment?Type=0001&HidTaskNO=CRC_001

  2. 尚未注册账号的认领者请点击下面链接(http://rl.amegroups.com)【注册】,账户激活后,请用户登录并进入【翻译】板块,选择【NO】:CRC_001, 即可认领文章, 只能选择状态为【待认领】的文章。

  3. 认领成功后,请用户自行选择【下载】来获取原文,同时请务必查看【要求】,并按要求来翻译文章。有问题请联系下列邮箱:kysj@amepc.org 。每人最多认领两篇。

 

认领截止日期:本次认领长期有效,直至认领完毕。

认领成功后,请在认领成功后的三周内将翻译稿及个人简介发送到 kysj@amepc.org

凡翻译质量通过审核的译者,可获得:

  1. 每翻译一篇文章,即可获得价值 200 元人民币的科研时间积分(200快币)以及免费登录视频数据库 ASVIDE,观看手术视频(积分限免)。

  2. 译文将刊登在本书上,并获赠本书中英文版各一本。

看到礼物心动了吗?想提高译稿审核的通过率吗?那就记得一定要按照上述要求来翻译哦!

 

comments powered by Disqus

附件